Clinical Trials Directory

Trials / Completed

CompletedNCT02884557

NKT Role in the Regulation of the Inflammatory Bowel Disease

Evaluation of the Expression of Natural Killer T Cells (NKT) Marker in the Gut of Patients With Primary Sclerosing Cholangitis (PSC) Complicated by an Inflammatory Bowel Disease (IBD)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
64 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). These diseases are a public health problem because they concern many patients (1 case in 1000). IBDs are characterized by dysregulated immune response against luminal antigens causing chronic inflammation of the gut in genetically predisposed individuals. Their exact cause is unknown and there is currently no cure. The primary sclerosing cholangitis (PSC) is a liver inflammatory disease of unknown origin that is known to be strongly associated with IBD. An important clinical observation highlights the mild symptoms of IBD when associated to the PSC. Conversely, treating PSC by liver transplant or immunosuppressive drugs is associated with a progression of intestinal inflammation. Based, on these clinical findings that suggest a protective effect regulator of liver inflammation on intestinal inflammation, and on the results obtained by our group in mouse models that identified the natural killer T cell (NKT) as essential in control of experimental colitis, the project aims to determine, using PCR, if the expression of NKT cell markers are increased in the colon of patients with PSC+IBD compared to patients with IBD alone or PSC alone.

Conditions

Interventions

TypeNameDescription
OTHERcollection of gut biopsies collection of blood samplesFour to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.

Timeline

Start date
2013-05-01
Primary completion
2019-08-27
Completion
2019-08-28
First posted
2016-08-31
Last updated
2020-08-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02884557. Inclusion in this directory is not an endorsement.